Jean-Pierre Bizzari , , M.D. ,

Dr. Bizzari brings extensive experience in oncology drug development. Dr. Bizzari was Group Head, Clinical Oncology Development at Celgene Corporation, a role he held since 2008. In this position, Dr. Bizzari was responsible for Celgene’s clinical development and operations-statistics teams across the U.S., Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology products including REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin) and ABRAXANE® (nab-paclitaxel). In addition, he was Chairman of Celgene’s hematology oncology development committee and a member of the company’s management committee. Prior to his role at Celgene, Dr. Bizzari was the Vice President, Clinical Oncology Development for Sanofi-Aventis where he oversaw the approval of Eloxatin® (oxaliplatin), Taxotere® (docetaxel) and Elitek® (rasburicase). Prior to that he was Vice President, Clinical Development Oncology for Sanofi-Synthelabo and had previously held the same role for Rhône-Poulenc Rorer. Dr. Bizzari is a member of the Scientific Advisory Board of France’s National Cancer Institute and is a board member of Transgene. Jean-Pierre Bizzari is a Doctor of Medicine and a graduate of the Nice Medical School and a specialist in oncology (training in Toronto and Montreal). Dr. Bizzari was also an assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. Dr. Bizzari serves on the Compensation Committee.

James M. Daly , ,

Mr. Daly is a biopharmaceutical executive with 30 years of experience leading U.S. and global businesses. Over the course of his career, he has built market-leading global franchises across multiple therapeutic categories, with a particular focus in oncology. Mr. Daly previously served as Executive Vice President and Chief Commercial Officer at Incyte Corporation from 2012 to 2015. During his time at Incyte, he was instrumental in re-accelerating the launch of Jakafi® and driving sustained growth. Prior to Incyte, Daly was Senior Vice President of North America Commercial Operations, Global Marketing and Commercial Development for Amgen, with P&L responsibility for all U.S. and Canadian businesses. Daly also served as Vice President and General Manager for Amgen’s Oncology Business Unit. His teams at Amgen were responsible for numerous successful product launches, including Aranesp®, Neulasta®, Vectibix®, Nplate®, Xgeva® and Prolia®. Mr. Daly began his career in the pharmaceutical industry at GlaxoSmithKline where he held positions of increasing responsibility over a 16 year period, including Senior Vice President and General Manager of the company’s Respiratory and Anti-infective Business Unit, where he led the U.S. launch of Advair®, and also served as the Senior Vice President of U.S. Marketing. He earned a Bachelor of Science degree in Pharmacy and Master of Business Administration from the State University of New York at Buffalo. Mr. Daly serves on the Nominating and Corporate Governance Committee.

Jeffrey W. Henderson , ,

Jeffrey W. Henderson brings nearly 30 years of financial, commercial and pharmaceutical industry expertise to the board, most recently serving for almost 10 years as chief financial officer of $100-billion health care products and services company, Cardinal Health. Mr. Henderson served as CFO of Cardinal Health from 2005 until the end of 2014, playing a key role in the company’s growth and transformation. During his tenure, the company acquired more than 30 companies, spun-off or sold multi-billion-dollar businesses and expanded into new geographies and market segments. In addition to his financial responsibilities, Mr. Henderson managed commercial operations in China and Canada. Prior to Cardinal Health, Mr. Henderson was president and general manager of Eli Lilly Canada Inc. and vice president and corporate controller of Eli Lilly & Co. He joined Lilly in 1998 as vice president and corporate treasurer. His prior experience included 10 years at General Motors Corp., where he served executive and managerial posts in Great Britain, Singapore, New York and Canada. He received his Bachelor of Science degree in electrical engineering from Kettering University, Flint, Mich., and his Master of Business Administration degree from Harvard Graduate School of Business Administration. Mr. Henderson serves on the Compensation Committee and as the Chair of the Audit Committee.

Kenneth J. Kelley , ,

Mr. Kelley brings over 30 years of entrepreneurial, venture capital, operational and technical biotechnology experience to Halozyme. Mr. Kelley currently serves on the Board of Directors of privately held PaxVax, Inc., and Jan Medical, Inc. Mr. Kelley is also a 2015 Advanced Leadership Initiative (ALI) Fellow at Harvard University focused global health. In 2007 Mr. Kelley founded PaxVax, Inc. and from 2008 until May 2015, Mr. Kelley served as the Chief Executive Officer. From April 2002 through June 2004, Mr. Kelley was a General Partner at Latterell Venture Partners, where he made investments in biotechnology and medical device startups. Mr. Kelley founded IntraBiotics Pharmaceuticals in January 1994 and over eight years served as CEO, Director and Chairman of the Board of Directors. Earlier, Mr. Kelley was an associate at Institutional Venture Partners (IVP), where he participated in the financing of twenty biotech and medical companies, fifteen of which became public companies. Prior to IVP, he was a consultant for McKinsey & Company and a scientist at Integrated Genetics (acquired by Genzyme). Mr. Kelley earned an M.B.A. from Stanford University and a B.A. in biochemical sciences from Harvard University. Mr. Kelley serves on the Audit Committee and as the Chair of the Nominating and Corporate Governance Committee.

Randal J. Kirk , ,

Mr. Kirk provides our Board with a wealth of strategic, operational and management experience. Mr. Kirk currently serves as the Senior Managing Director and Chief Executive Officer of Third Security, LLC, an investment management firm founded by Mr. Kirk. Mr. Kirk also currently serves as Chairman of the Board of Directors of Intrexon Corporation (NYSE:XON) since February 2008 and Chief Executive Officer since April 2009. Additionally, Mr. Kirk founded and became Chairman of the Board of New River Pharmaceuticals Inc. (previously traded on Nasdaq prior to its acquisition by Shire plc in 2007) in 1996, and was President and Chief Executive Officer between October 2001 and April 2007. Mr. Kirk began his professional career in the private practice of law. Previously, Mr. Kirk served as a member of the Board of Directors of Scios, Inc. (previously traded on Nasdaq prior to its acquisition by Johnson & Johnson) between February 2000 and May 2002, and as a member of the Board of Directors of Clinical Data, Inc. (previously traded on Nasdaq prior to its acquisition by Forest Laboratories, Inc. in April 2011) from September 2002 to April 2011, and was Chairman of the Board from December 2004 to April 2011. Mr. Kirk currently serves in a number of additional capacities including as a member of the Board of Directors of ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) since January 2011. Mr. Kirk served on the Board of Visitors of Radford University from July 2003 to June 2009, was Rector of the Board from September 2006 to September 2008, and served on the Board of Directors of the Radford University Foundation, Inc. from September 1998 to May 2011. He served on the Board of Visitors of the University of Virginia and Affiliated Schools from July 2009 to October 2012, on the Virginia Advisory Council on Revenue Estimates from July 2006 to October 2012 and on the Governor's Economic Development and Jobs Creation Commission from April 2010 to October 2012. Mr. Kirk received a B.A. in Business from Radford University and a J.D. from the University of Virginia. Mr. Kirk serves on the Nominating and Corporate Governance Committee.

Connie L. Matsui , , , Chairman of the Board

Ms. Matsui brings to our Board over 16 years of general management experience in the biotechnology industry. She retired from Biogen Idec Inc. in January 2009 as the Executive Vice President, Knowledge and Innovation Networks. She served as an Executive Committee member at both Biogen Idec and IDEC Pharmaceuticals, a predecessor of Biogen Idec. Among the major roles she played after joining IDEC Pharmaceuticals in November 1992 were: Senior Vice President, overseeing investor relations, corporate communications, human resources, project management and strategic planning; Collaboration Chair for the late stage development and commercialization of rituximab (tradenames: Rituxan®, MabThera®) in partnership with Roche and Genentech; and Project Leader for Zevalin®, the first radioimmunotherapy approved by the U.S. FDA. Prior to entering the biotechnology industry, Ms. Matsui worked for Wells Fargo Bank in general management, marketing and human resources. Ms. Matsui has been active on a number of not-for-profit boards and served as National President/Board Chair of the Girl Scouts of the USA from 1999 to 2002. Ms. Matsui earned B.A. and M.B.A. degrees from Stanford University. Ms. Matsui serves as the Chair of the Board of Directors and as the Chair of the Compensation Committee.

Matthew L. Posard , ,

Matthew Posard is a member of the Audit and Nominating and Corporate Governance Committees on the Halozyme board and also serves on the boards of DermTech, SlipChip Corporation and Omicia. Since February 2017, Mr. Posard has served as President and Chief Commercial Officer of GenePeaks, Inc., a computational genomics company. He was previously Executive Vice President, Chief Commercial Officer of Trovagene, Inc., where he oversaw sales, marketing, client services, market and business development until April 2016. Previously, Mr. Posard was Senior Vice President and General Manager of Illumina, Inc.’s New Emerging Opportunity Business, where he oversaw the development and transfer of Illumina technology into new markets. He joined Illumina in 2006 as Vice President of Global Marketing and served as Vice President of Global Sales from 2007 to 2011, leading Illumina’s successful commercial entry into the life science sequencing market. Prior to joining Illumina, Mr. Posard held various positions in strategic and product marketing at Gen-Probe, Inc., helping the company attain leading market positions in DNA probe-based infectious disease diagnostics and blood banking. Previously, he oversaw global marketing at Biosite, Inc., where he was instrumental in the successful introduction of the company’s BNP congestive heart failure biomarker and its BNP co-marketing collaboration with Beckman Coulter. Mr. Posard holds a B.A. degree in Quantitative Economics and Decision Science from the University of California, San Diego.

Helen Torley , , M.B. Ch. B., M.R.C.P. ,

Dr. Helen Torley joined Halozyme in January 2014 as President and Chief Executive Officer, and is a member of Halozyme’s Board of Directors. Throughout her career, Dr. Torley has led several successful product launches, including Kyprolis ®, Prolia®, Sensipar®, and Miacalcin®. Dr. Torley previously served as Executive Vice President and Chief Commercial Officer for Onyx Pharmaceuticals overseeing the collaboration with Bayer on Nexavar® and Stivarga ® and the US launch of Kyprolis®. She was responsible for the development of Onyx's commercial capabilities in ex-US markets and in particular, in Europe. Prior to Onyx, Dr. Torley spent 14 years in management positions at Amgen, serving as General Manger of both the US Nephrology Business Unit and the US Bone Health Business Unit. From 1997 to 2002, she held various senior management positions at Bristol-Myers Squibb, including Regional Vice President of Cardiovascular and Metabolic Sales and Head of Cardiovascular Global Marketing. She began her career at Sandoz/Novartis, where she ultimately served as Vice President of Medical Affairs, developing and conducting post-marketing clinical studies across all therapeutic areas, including oncology. Before joining the industry, Dr. Torley was in medical practice as a senior registrar in rheumatology at the Royal Infirmary in Glasgow, Scotland. Dr. Torley received her Bachelor of Medicine and Bachelor of Surgery degrees (M.B. Ch.B.) from the University of Glasgow, and is a Member of the Royal College of Physicians (M.R.C.P).


You are now leaving Halozyme is not responsible for or endorses the content of the linked site.